ArticleFrontiers in endocrinology2026
Interaction between progesterone exposure duration and blastocyst expansion stage on live birth following frozen-thawed transfer of day-6 blastocysts.
Article in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Optimizing the Endometrial Factor in Recurrent Implantation Failure: From Established Diagnostics to Mechanism-Informed Management.Journal of clinical medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To determine the optimal duration of progesterone exposure before frozen-thawed embryo transfer (FET) of day-6 blastocysts. Methods: This retrospective cohort study included 2,058 women who underwent single frozen-thawed day-6 blastocyst transfer between August 2021 and August 2024. Univariable and multivariable logistic regression models were applied to evaluate the association between the duration of progesterone exposure and live birth rate (LBR). Subgroup analyzes with formal interaction testing were conducted to assess potential effect modification by blastocyst expansion stage and other covariates. Results: Overall LBR was comparable between the day-6 and day-7 progesterone groups (42.8% vs. 41.9%; Conclusion: While overall LBRs were similar between day-6 and day-7 progesterone regimens for day-6 blastocyst, optimal progesterone duration differed by blastocyst expansion stage: early-stage blastocysts benefited from day-6 exposure, whereas late-stage blastocysts derived benefit from day-7 exposure.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.